[4-chloro-2-methoxy-3-[[4-(trifluoromethyl)phenyl]methyl]quinolin-6-yl]-(4-chlorophenyl)-(2-methyl-1H-imidazol-5-yl)methanol

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二芳基庚烷
• 英文名称: [4-chloro-2-methoxy-3-[[4-(trifluoromethyl)phenyl]methyl]quinolin-6-yl]-(4-chlorophenyl)-(2-methyl-1H-imidazol-5-yl)methanol
• 化学式: C₂₉H₂₂Cl₂F₃N₃O₂
• 分子量: 572.4
• InChiKey: QUEZQUXFLMLGCQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.4
• 重原子数：
  39
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  71
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• EP2909192A1
  申请人：——

  公开号：EP2909192A1

  公开（公告）日：2015-08-26
• [EN] METHYLENE LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T<br/>[FR] MODULATEURS DE ROR-GAMMA-T DE TYPE QUINOLINYLE À LIAISON MÉTHYLÈNE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2014062658A1

  公开（公告）日：2014-04-24

  The present invention comprises compounds of Formula (I), wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.